Kamiren (Doxazosin)

Doxazosin, the active ingredient in Kamiren, is a alpha-1 adrenergic antagonist presented as an oral dosage form for oral use. It is employed to lower high blood pressure and to relieve urinary obstruction caused by an enlarged prostate in adult patients.

GNH USA supplies Kamiren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the alpha‑1 adrenergic pathway to manage cardiovascular and urological conditions. - Hypertension: lowers systolic and diastolic blood pressure by vasodilation, helping achieve target blood pressure goals. - Benign prostatic hyperplasia (BPH): relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms such as urgency and nocturia.

Doxazosin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or tiredness. - Nasal congestion. - Peripheral edema. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Marked hypotension or syncope. - Priapism (prolonged erection). - Severe allergic reactions, including rash, itching, or swelling. - Angioedema affecting face, lips, or throat. - Liver function abnormalities. - Cardiac arrhythmias in susceptible individuals.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Renal or hepatic impairment: dose may need adjustment; monitor organ function. - Concomitant antihypertensives: assess for additive blood‑pressure lowering effects. - Elderly patients: start at lower doses and titrate slowly. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Doxazosin can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other alpha‑1 blockers (e.g., terazosin, prazosin): risk of profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): can cause severe drops in blood pressure.

Moderate Interactions (Monitor Closely):\n- Diuretics and other antihypertensives: additive blood‑pressure effects. - Beta‑blockers: may enhance bradycardia. - NSAIDs: may blunt antihypertensive response. - Lithium: monitor serum lithium levels. - Antidepressants with noradrenergic activity: watch for enhanced orthostatic effects.